Page last updated: 2024-10-21

pk 11195 and Acute Confusional Senile Dementia

pk 11195 has been researched along with Acute Confusional Senile Dementia in 32 studies

PK-11195 : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 1-(2-chlorophenyl)isoquinoline-3-carboxylic acid with the amino group of sec-butylmethylamine

Research Excerpts

ExcerptRelevanceReference
"Twenty-six (62%) of 42 mild cognitive impairment cases showed a raised cortical amyloid load compared to healthy controls."1.46Brain inflammation accompanies amyloid in the majority of mild cognitive impairment cases due to Alzheimer's disease. ( Aanerud, J; Amidi, A; Borghammer, P; Brooks, DJ; Brændgaard, H; Edison, P; Eriksson, BO; Eskildsen, SF; Gottrup, H; Hansen, KV; Hinz, R; Ismail, R; Lund, TE; Mårup, FH; Parbo, P; Pavese, N; Stokholm, MG; Tietze, A, 2017)
"Longitudinally, Alzheimer's disease subjects showed an increase in microglial activation."1.46An early and late peak in microglial activation in Alzheimer's disease trajectory. ( Brooks, DJ; Edison, P; Fan, Z; Okello, A, 2017)
"10 AD, 10 mild cognitive impairment (MCI), 11 PD dementia (PDD), and 16 controls underwent magnetic resonance imaging, [11C](R)PK11195 (1-[2-chlorophenyl]-N-methyl-N-[1-methyl-propyl]-3-isoquinoline carboxamide), [11C]PIB (11C-Pittsburgh compound B), [18F]FDG-PET (18F-2-fluoro-2-deoxyglucose positron emission tomography) scans."1.42Influence of microglial activation on neuronal function in Alzheimer's and Parkinson's disease dementia. ( Ahmed, I; Aman, Y; Brooks, DJ; Chetelat, G; Edison, P; Fan, Z; Landeau, B; Ray Chaudhuri, K, 2015)
"At baseline, patients with Alzheimer's disease showed significantly increased microglial activation compared to the control subjects."1.42Longitudinal influence of microglial activation and amyloid on neuronal function in Alzheimer's disease. ( Brooks, DJ; Edison, P; Fan, Z; Okello, AA, 2015)
"The pathological features in Alzheimer's disease (AD) brain include the accumulation and deposition of β-amyloid (Aβ), activation of astrocytes and microglia and disruption of cholinergic neurotransmission."1.39³H-deprenyl and ³H-PIB autoradiography show different laminar distributions of astroglia and fibrillar β-amyloid in Alzheimer brain. ( Bergfors, A; Gillberg, PG; Marutle, A; Nennesmo, I; Ni, R; Nordberg, A; Voytenko, L; Yu, W, 2013)
"Data from controls, mild cognitive impairment patients, and patients with Alzheimer's disease were analyzed using various kinetic models including plasma input, the simplified reference tissue model (RPM) and RPM with vascular correction (RPMV(b))."1.38Optimization of supervised cluster analysis for extracting reference tissue input curves in (R)-[(11)C]PK11195 brain PET studies. ( Boellaard, R; Hinz, R; Lammertsma, AA; Schuitemaker, A; Tomasi, G; Turkheimer, FE; van Berckel, BN; Yaqub, M, 2012)
"Inflammation in Alzheimer's disease (AD) may be assessed using (R)-[(11)C]PK11195 and positron emission tomography."1.34Evaluation of reference regions for (R)-[(11)C]PK11195 studies in Alzheimer's disease and mild cognitive impairment. ( Boellaard, R; Jonker, C; Kloet, RW; Kropholler, MA; Lammertsma, AA; Lubberink, MJ; Scheltens, P; Schuitemaker, A; van Berckel, BN, 2007)
"Ferulic acid is a natural compound that expresses antioxidant and anti-inflammatory activities."1.32Attenuation of chronic neuroinflammation by a nitric oxide-releasing derivative of the antioxidant ferulic acid. ( Gasparini, L; Hauss-Wegrzyniak, B; Maucci, R; McGann-Gramling, K; Ongini, E; Ronchetti, D; Rosi, S; Wenk, GL, 2004)
"By contrast, patients with Alzheimer's disease showed significantly increased regional [11C](R)-PK11195 binding in the entorhinal, temporoparietal, and cingulate cortex."1.31In-vivo measurement of activated microglia in dementia. ( Banati, RB; Brooks, DJ; Cagnin, A; Gunn, RN; Jones, T; Kennedy, AM; Myers, R; Turkheimer, FE, 2001)
"The aetiology and pathogenesis of Alzheimer's disease are currently poorly understood, but symptomatic disease is associated with amyloid plaques, neurofibrillary tangles, neuronal loss and numerous alterations of neurotransmitter systems in the CNS."1.29Increased monoamine oxidase B activity in plaque-associated astrocytes of Alzheimer brains revealed by quantitative enzyme radioautography. ( Cesura, AM; Chan-Palay, V; Da Prada, M; Huber, G; Löffler, J; Luque, JM; Richards, JG; Saura, J, 1994)

Research

Studies (32)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's3 (9.38)18.2507
2000's12 (37.50)29.6817
2010's15 (46.88)24.3611
2020's2 (6.25)2.80

Authors

AuthorsStudies
Kim, T2
Yang, HY1
Park, BG1
Jung, SY2
Park, JH2
Park, KD2
Min, SJ1
Tae, J1
Yang, H1
Cho, S1
Cho, SJ2
Song, H1
Mook-Jung, I1
Lee, J2
Pae, AN2
Son, WS1
Morshed, MN1
Londhe, AM1
Park, WK1
Lim, SM1
Jeong, KS1
Parbo, P2
Madsen, LS1
Ismail, R2
Zetterberg, H1
Blennow, K1
Eskildsen, SF2
Vorup-Jensen, T1
Brooks, DJ11
Ni, R2
Röjdner, J1
Voytenko, L2
Dyrks, T1
Thiele, A1
Marutle, A2
Nordberg, A2
Hansen, KV1
Amidi, A1
Mårup, FH1
Gottrup, H1
Brændgaard, H1
Eriksson, BO1
Lund, TE1
Tietze, A1
Edison, P9
Pavese, N3
Stokholm, MG1
Borghammer, P1
Hinz, R3
Aanerud, J1
Christensen, A1
Pike, CJ2
Barron, AM1
Garcia-Segura, LM1
Caruso, D1
Jayaraman, A1
Lee, JW1
Melcangi, RC1
Gillberg, PG1
Bergfors, A1
Yu, W1
Nennesmo, I1
Hommet, C1
Mondon, K1
Camus, V1
Ribeiro, MJ1
Beaufils, E1
Arlicot, N1
Corcia, P1
Paccalin, M1
Minier, F1
Gosselin, T1
Page, G1
Guilloteau, D1
Chalon, S1
Fan, Z4
Aman, Y1
Ahmed, I1
Chetelat, G1
Landeau, B1
Ray Chaudhuri, K1
Okello, AA1
Femminella, GD1
Ninan, S1
Atkinson, R1
Yokokura, M1
Terada, T1
Bunai, T1
Nakaizumi, K1
Takebayashi, K1
Iwata, Y1
Yoshikawa, E1
Futatsubashi, M1
Suzuki, K1
Mori, N1
Ouchi, Y1
Okello, A2
Tomasi, G2
Bertoldo, A1
Roncaroli, F1
Singh, P1
Gerhard, A3
Cobelli, C1
Turkheimer, FE6
Archer, HA2
Hammers, A2
Tai, YF2
Fox, N2
Kennedy, A2
Rossor, M2
Kennedy, J1
Bullock, R1
Walker, Z1
Wiley, CA2
Lopresti, BJ2
Venneti, S2
Price, J1
Klunk, WE2
DeKosky, ST1
Mathis, CA2
Roberts, JC1
Friel, SL1
Roman, S1
Perren, M1
Harper, A1
Davis, JB1
Richardson, JC1
Virley, D1
Medhurst, AD1
Yaqub, M1
van Berckel, BN4
Schuitemaker, A4
Lammertsma, AA4
Boellaard, R4
Rapic, S1
Backes, H1
Viel, T1
Kummer, MP1
Monfared, P1
Neumaier, B1
Vollmar, S1
Hoehn, M1
Van der Linden, A1
Heneka, MT1
Jacobs, AH1
Kropholler, MA3
van der Flier, WM1
Kloet, RW3
van der Doef, TF1
Knol, DL1
Windhorst, AD1
Luurtsema, G1
Barkhof, F1
Jonker, C3
Scheltens, P3
Versijpt, JJ1
Dumont, F1
Van Laere, KJ1
Decoo, D1
Santens, P1
Audenaert, K1
Achten, E1
Slegers, G1
Dierckx, RA1
Korf, J1
Wenk, GL1
McGann-Gramling, K1
Hauss-Wegrzyniak, B1
Ronchetti, D1
Maucci, R1
Rosi, S1
Gasparini, L1
Ongini, E1
Anderson, AN1
Lubberink, MJ1
Wang, G1
Hamilton, RL1
Apte, UM1
Saura, J1
Luque, JM1
Cesura, AM1
Da Prada, M1
Chan-Palay, V1
Huber, G1
Löffler, J1
Richards, JG1
Groom, GN1
Junck, L1
Foster, NL1
Frey, KA1
Kuhl, DE1
Cagnin, A1
Kennedy, AM1
Gunn, RN1
Myers, R1
Jones, T1
Banati, RB1
Bidder, M1
Ratzoni, G1
Weizman, A1
Blumensohn, R1
Norymberg, M1
Tyano, S1
Gavish, M1

Clinical Trials (3)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
The Relationship Between Neuropsychological Testing and MRI, PET and Blood Biomarkers in Neurodegenerative Disease (COBRE - Project 1): AIM 2[NCT03702816]Phase 224 participants (Actual)Interventional2018-12-13Terminated (stopped due to GE180 has limited Blood - brain barrier permeation, reducing its utility in neuroinflammation. COVID19 created supply chain issues, impacting enrollment.)
Brain Inflammation In Major Depressive Disorder[NCT01851356]61 participants (Actual)Observational2013-05-08Completed
Assessment of [11C]ER-176 to Image Translocator Protein in Brain and Whole-Body of Healthy Subjects[NCT02147392]Early Phase 116 participants (Actual)Interventional2014-05-14Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Cingulate GE180 Standardized Uptake Value Ratio (SUVR)

Cingulate SUVR- GE180 binding potential in the cingulate ROI, as a marker of cingulate neuroinflammation. Cingulate neuroinflammation would be expected to relate to cingulate AD pathology, and given known cingulate lobe role in executive system function, is hypothesized to relate to measures of executive function in particular, with greater cingulate GE180 relating to poorer cognitive function. (NCT03702816)
Timeframe: Baseline (Single scan)

InterventionSUVR (Mean)
Control0.9994
Mild Cognitive Impairment1.0387
Alzheimer's Disease1.0554
Parkinson's Disease0.9893

Dementia Rating Score

DRS- The Dementia Rating Scale is a comprehensive, but relatively brief assessment of overall cognitive functioning. The measure consists of items testing memory, attention, executive skills, and visuospatial skill, for a total of 144 points. A score of less than 124 is indicative of dementia level cognitive functioning. A higher score indicates a better outcome. (NCT03702816)
Timeframe: Baseline (Pre-scan)

Interventionscore on a scale (Mean)
Control139.2
Mild Cognitive Impairment130.4
Alzheimer's Disease120.3
Parkinson's Disease139.3

Executive Function Composite Score (Z-score)

The executive function composite score is comprised from data from two gold-standard clinical measures of set-shifting and inhibition (Trail Making Test, part B; Delis Kaplan Executive Functioning Scale Color Word Inhibition, inhibition score). The raw score for each individual assessment is corrected for age based on published normative data for each test. These adjusted scores (T scores and/or scaled scores) are converted to z-scores, then the two z-scores are averaged together to create the composite score. A higher value is indicative of better executive function, a lower value is indicative of worse executive function. A z-score of 0 represents the sample mean. Composite Z-scores do not have direct clinical relevance. (NCT03702816)
Timeframe: Baseline (Pre-scan)

Interventionz score (Mean)
Control0.572
Mild Cognitive Impairment-0.011
Alzheimer's Disease-1.361
Parkinson's Disease0.029

Frontal GE180 Standardized Uptake Value Ratio (SUVR)

Frontal SUVR- GE180 binding potential in the frontal cortical ROI, as a marker of frontal neuroinflammation. Frontal neuroinflammation would be expected to relate to frontal lobe AD pathology, and given known frontal lobe role in executive system function, is hypothesized to relate to measures of executive function in particular, and also to memory and language dysfunction, as these have executive components. Greater frontal lobe GE180 is expected to relate to poorer cognitive function. (NCT03702816)
Timeframe: Baseline (Single scan)

InterventionSUVR (Mean)
Control0.8893
Mild Cognitive Impairment0.9436
Alzheimer's Disease0.8855
Parkinson's Disease0.8850

Language Composite Score (Z-score)

The language composite score is comprised from data from two gold-standard clinical measures of confrontation naming and semantic fluency (Boston Naming Test; Animal Naming Test). The raw score for the Animal Naming Test is converted directly to a z-score based on published normative data. The Boston Naming Test is corrected for age based on published normative data, resulting in a scaled score, which is then converted to a z-score. Then the two z-scores are averaged together to create the composite score. A higher value is indicative of better language function, a lower value is indicative of worse language function. A z-score of 0 represents the sample mean. Composite Z-scores do not have direct clinical relevance. (NCT03702816)
Timeframe: Baseline (Pre-scan)

Interventionz score (Mean)
Control0.584
Mild Cognitive Impairment-0.234
Alzheimer's Disease-0.7272
Parkinson's Disease0.541

Memory Composite Score (Z-score)

The memory composite score is comprised from data from two gold-standard clinical measures of verbal and nonverbal memory (Rey Auditory Verbal Learning Test, delayed recall score; Brief Visuospatial Memory Test, Revised, delayed recall score). The raw score for each individual assessment is corrected for age based on published normative data for each test. These adjusted scores (T scores and/or scaled scores) are converted to z-scores, then the two z-scores are averaged together to create the composite score. A higher value is indicative of better memory function, a lower value is indicative of worse memory function. A z-score of 0 represents the sample mean. Composite Z-scores do not have direct clinical relevance. (NCT03702816)
Timeframe: Baseline (Pre-scan)

Interventionz score (Mean)
Control0.367
Mild Cognitive Impairment-0.675
Alzheimer's Disease-2.483
Parkinson's Disease-0.404

Montreal Cognitive Assessment Score (MoCA)

MoCA -The Montreal Cognitive Assessment is a brief screening tool, originally designed to detect patients with MCI in a memory disorders clinic [10]. Standard administration consists of 12 individual tasks grouped into seven cognitive domains (visuospatial/executive, naming; attention, language, abstraction, memory, and orientation). Task performance is summed generating both domain and a total score. An education correction of one point is added to the total score for individuals with 12 years of education or less. Scores range from 0-30, with a score of 26 or less indicating cognitive impairment. (NCT03702816)
Timeframe: Baseline (Pre-scan)

Interventionscore on a scale (Mean)
Control26.0
Mild Cognitive Impairment23.4
Alzheimer's Disease18.3
Parkinson's Disease27.5

Parietal GE180 Standardized Uptake Value Ratio (SUVR)

Parietal SUVR - GE180 binding potential in the parietal cortical ROI, as a marker of parietal neuroinflammation. Parietal neuroinflammation would be expected to relate to parietal lobe AD pathology, and given known parietal lobe role in visual and executive system function, is hypothesized to relate to measures of visuospatial and executive skills in particular, with greater parietal lobe GE180 relating to poorer cognitive function. (NCT03702816)
Timeframe: Baseline (Single scan)

InterventionSUVR (Mean)
Control0.8701
Mild Cognitive Impairment0.9241
Alzheimer's Disease0.8847
Parkinson's Disease0.8562

Speed Composite Score (Z-score)

The speed composite score is comprised from data from two gold-standard clinical measures of speeded attention and psychomotor speed (Trail Making Test, part A; Symbol Digit Modalities Test, oral version). The raw score for the Symbol Digit Modalities Test, oral version is converted directly to a z-score based on published normative data. The Trail making Test, part A is corrected for age based on published normative data, resulting in a T-score, which is then converted to a z-score. Then the two z-scores are averaged together to create the composite score. A higher value is indicative of better speed function, a lower value is indicative of worse speed function. A z-score of 0 represents the sample mean. Composite Z-scores do not have direct clinical relevance. (NCT03702816)
Timeframe: Baseline (Pre-scan)

Interventionz score (Mean)
Control0.285
Mild Cognitive Impairment-0.013
Alzheimer's Disease-1.585
Parkinson's Disease-0.731

Temporal GE180 Standardized Uptake Value Ratio (SUVR)

Temporal SUVR-- GE180 binding potential in the temporal cortical ROI, as a marker of temporal neuroinflammation. Temporal neuroinflammation would be expected to relate to temporal lobe AD pathology, and given known temporal lobe role in memory and language system function, is hypothesized to relate to measures of memory in particular, with greater temporal lobe GE180 relating to poorer memory and language function. (NCT03702816)
Timeframe: Baseline (Single scan)

InterventionSUVR (Mean)
Control0.9127
Mild Cognitive Impairment0.9779
Alzheimer's Disease0.9146
Parkinson's Disease0.8899

Whole Brain GE180 Standardized Uptake Value Ratio (SUVR)

Whole Brain GE180- GE180 binding potential in the whole brain, as a marker of global neuroinflammation. Global neuroinflammation would be expected to relate to more widespread pathology on average, and is hypothesized to relate to global measures of cognition, including the MoCA and DRS, with greater whole brain GE180 relating to poorer cognitive function overall. (NCT03702816)
Timeframe: Baseline (Single scan)

InterventionSUVR (Mean)
Control0.9179
Mild Cognitive Impairment0.9711
Alzheimer's Disease0.9351
Parkinson's Disease0.9051

Reviews

1 review available for pk 11195 and Acute Confusional Senile Dementia

ArticleYear
Neuroinflammation and β amyloid deposition in Alzheimer's disease: in vivo quantification with molecular imaging.
    Dementia and geriatric cognitive disorders, 2014, Volume: 37, Issue:1-2

    Topics: Aged; Aged, 80 and over; Alzheimer Disease; Amyloid beta-Peptides; Aniline Compounds; Benzothiazoles

2014

Other Studies

31 other studies available for pk 11195 and Acute Confusional Senile Dementia

ArticleYear
Discovery of benzimidazole derivatives as modulators of mitochondrial function: A potential treatment for Alzheimer's disease.
    European journal of medicinal chemistry, 2017, Jan-05, Volume: 125

    Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Benzimidazoles; Cognition; Humans; Ligands; Male;

2017
Discovery of thienopyrrolotriazine derivatives to protect mitochondrial function against Aβ-induced neurotoxicity.
    European journal of medicinal chemistry, 2017, Dec-01, Volume: 141

    Topics: Adenosine Triphosphate; Alzheimer Disease; Amyloid beta-Peptides; Animals; Dogs; Dose-Response Relat

2017
Low plasma neurofilament light levels associated with raised cortical microglial activation suggest inflammation acts to protect prodromal Alzheimer's disease.
    Alzheimer's research & therapy, 2020, 01-02, Volume: 12, Issue:1

    Topics: Aged; Alzheimer Disease; Biomarkers; Carbon Radioisotopes; Cognitive Dysfunction; Female; Humans; In

2020
In vitro Characterization of the Regional Binding Distribution of Amyloid PET Tracer Florbetaben and the Glia Tracers Deprenyl and PK11195 in Autopsy Alzheimer's Brain Tissue.
    Journal of Alzheimer's disease : JAD, 2021, Volume: 80, Issue:4

    Topics: Aged; Aged, 80 and over; Alzheimer Disease; Amyloid beta-Peptides; Aniline Compounds; Autopsy; Brain

2021
Brain inflammation accompanies amyloid in the majority of mild cognitive impairment cases due to Alzheimer's disease.
    Brain : a journal of neurology, 2017, Jul-01, Volume: 140, Issue:7

    Topics: Aged; Aged, 80 and over; Alzheimer Disease; Amyloid; Aniline Compounds; Case-Control Studies; Cerebr

2017
TSPO ligand PK11195 improves Alzheimer-related outcomes in aged female 3xTg-AD mice.
    Neuroscience letters, 2018, 09-14, Volume: 683

    Topics: Aging; Alzheimer Disease; Amyloid beta-Peptides; Animals; Brain; Female; Isoquinolines; Ligands; Maz

2018
Ligand for translocator protein reverses pathology in a mouse model of Alzheimer's disease.
    The Journal of neuroscience : the official journal of the Society for Neuroscience, 2013, May-15, Volume: 33, Issue:20

    Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Benzodiazepinones

2013
³H-deprenyl and ³H-PIB autoradiography show different laminar distributions of astroglia and fibrillar β-amyloid in Alzheimer brain.
    Journal of neuroinflammation, 2013, Jul-23, Volume: 10

    Topics: Aged; Alzheimer Disease; Amyloid beta-Peptides; Aniline Compounds; Astrocytes; Autoradiography; Benz

2013
Influence of microglial activation on neuronal function in Alzheimer's and Parkinson's disease dementia.
    Alzheimer's & dementia : the journal of the Alzheimer's Association, 2015, Volume: 11, Issue:6

    Topics: Alzheimer Disease; Amyloid; Brain; Brain Mapping; Carbon Radioisotopes; Cognitive Dysfunction; Fluor

2015
Longitudinal influence of microglial activation and amyloid on neuronal function in Alzheimer's disease.
    Brain : a journal of neurology, 2015, Volume: 138, Issue:Pt 12

    Topics: Aged; Alzheimer Disease; Amyloid; Aniline Compounds; Brain; Case-Control Studies; Disease Progressio

2015
Does Microglial Activation Influence Hippocampal Volume and Neuronal Function in Alzheimer's Disease and Parkinson's Disease Dementia?
    Journal of Alzheimer's disease : JAD, 2016, Volume: 51, Issue:4

    Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antineoplastic Agents; Brain Mapping; Cognition; Female;

2016
Depiction of microglial activation in aging and dementia: Positron emission tomography with [
    Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism, 2017, Volume: 37, Issue:3

    Topics: Acetamides; Aged; Aging; Alzheimer Disease; Brain; Carbon Radioisotopes; Dementia; Humans; Isoquinol

2017
An early and late peak in microglial activation in Alzheimer's disease trajectory.
    Brain : a journal of neurology, 2017, 03-01, Volume: 140, Issue:3

    Topics: Aged; Alzheimer Disease; Aniline Compounds; Antineoplastic Agents; Brain Mapping; Carbon Radioisotop

2017
Novel reference region model reveals increased microglial and reduced vascular binding of 11C-(R)-PK11195 in patients with Alzheimer's disease.
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2008, Volume: 49, Issue:8

    Topics: Alzheimer Disease; Binding Sites; Brain; Carbon Radioisotopes; Humans; Isoquinolines; Microglia; Mod

2008
Microglia, amyloid, and cognition in Alzheimer's disease: An [11C](R)PK11195-PET and [11C]PIB-PET study.
    Neurobiology of disease, 2008, Volume: 32, Issue:3

    Topics: Aged; Alzheimer Disease; Amyloid; Aniline Compounds; Carbon Radioisotopes; Cerebral Cortex; Cluster

2008
Microglial activation and amyloid deposition in mild cognitive impairment: a PET study.
    Neurology, 2009, Jan-06, Volume: 72, Issue:1

    Topics: Aged; Alzheimer Disease; Amyloid beta-Peptides; Aniline Compounds; Benzothiazoles; Brain Mapping; Ca

2009
Carbon 11-labeled Pittsburgh Compound B and carbon 11-labeled (R)-PK11195 positron emission tomographic imaging in Alzheimer disease.
    Archives of neurology, 2009, Volume: 66, Issue:1

    Topics: Aged; Aged, 80 and over; Alzheimer Disease; Amyloid beta-Peptides; Aniline Compounds; Antineoplastic

2009
Autoradiographical imaging of PPARgamma agonist effects on PBR/TSPO binding in TASTPM mice.
    Experimental neurology, 2009, Volume: 216, Issue:2

    Topics: Acetamides; Age Factors; Aged; Aged, 80 and over; Alzheimer Disease; Amyloid beta-Peptides; Amyloid

2009
Optimization of supervised cluster analysis for extracting reference tissue input curves in (R)-[(11)C]PK11195 brain PET studies.
    Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism, 2012, Volume: 32, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Algorithms; Alzheimer Disease; Blood Volume; Carbon Radioisotopes; C

2012
Imaging microglial activation and glucose consumption in a mouse model of Alzheimer's disease.
    Neurobiology of aging, 2013, Volume: 34, Issue:1

    Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Analysis of Variance; Anim

2013
Microglial activation in Alzheimer's disease: an (R)-[¹¹C]PK11195 positron emission tomography study.
    Neurobiology of aging, 2013, Volume: 34, Issue:1

    Topics: Aged; Alzheimer Disease; Analysis of Variance; Brain Mapping; Carbon Radioisotopes; Cluster Analysis

2013
Assessment of neuroinflammation and microglial activation in Alzheimer's disease with radiolabelled PK11195 and single photon emission computed tomography. A pilot study.
    European neurology, 2003, Volume: 50, Issue:1

    Topics: Aged; Aged, 80 and over; Alzheimer Disease; Brain Mapping; Dominance, Cerebral; Encephalitis; Female

2003
Attenuation of chronic neuroinflammation by a nitric oxide-releasing derivative of the antioxidant ferulic acid.
    Journal of neurochemistry, 2004, Volume: 89, Issue:2

    Topics: Alzheimer Disease; Animals; Anti-Inflammatory Agents; Antioxidants; Butanes; Chronic Disease; Coumar

2004
Evaluation of methods for generating parametric (R-[11C]PK11195 binding images.
    Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism, 2007, Volume: 27, Issue:9

    Topics: Adult; Aged; Alzheimer Disease; Brain; Carbon Radioisotopes; Evaluation Studies as Topic; Humans; Im

2007
A systematic comparison of kinetic modelling methods generating parametric maps for [(11)C]-(R)-PK11195.
    NeuroImage, 2007, May-15, Volume: 36, Issue:1

    Topics: Alzheimer Disease; Brain; Brain Mapping; Carbon Radioisotopes; Cluster Analysis; Computer Graphics;

2007
Evaluation of reference regions for (R)-[(11)C]PK11195 studies in Alzheimer's disease and mild cognitive impairment.
    Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism, 2007, Volume: 27, Issue:12

    Topics: Adult; Aged; Algorithms; Alzheimer Disease; Antineoplastic Agents; Blood Volume; Cluster Analysis; C

2007
PK11195 labels activated microglia in Alzheimer's disease and in vivo in a mouse model using PET.
    Neurobiology of aging, 2009, Volume: 30, Issue:8

    Topics: Aged; Aged, 80 and over; Aging; Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Astrocyt

2009
Increased monoamine oxidase B activity in plaque-associated astrocytes of Alzheimer brains revealed by quantitative enzyme radioautography.
    Neuroscience, 1994, Volume: 62, Issue:1

    Topics: Aged; Aged, 80 and over; Alzheimer Disease; Astrocytes; Autoradiography; Brain; Female; Humans; Imag

1994
PET of peripheral benzodiazepine binding sites in the microgliosis of Alzheimer's disease.
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 1995, Volume: 36, Issue:12

    Topics: Aged; Aged, 80 and over; Alzheimer Disease; Brain; Carbon Radioisotopes; Case-Control Studies; Deoxy

1995
In-vivo measurement of activated microglia in dementia.
    Lancet (London, England), 2001, Aug-11, Volume: 358, Issue:9280

    Topics: Adult; Aged; Aged, 80 and over; Alzheimer Disease; Atrophy; Brain; Carbon Radioisotopes; Case-Contro

2001
In-vivo measurement of activated microglia in dementia.
    Lancet (London, England), 2001, Aug-11, Volume: 358, Issue:9280

    Topics: Adult; Aged; Aged, 80 and over; Alzheimer Disease; Atrophy; Brain; Carbon Radioisotopes; Case-Contro

2001
In-vivo measurement of activated microglia in dementia.
    Lancet (London, England), 2001, Aug-11, Volume: 358, Issue:9280

    Topics: Adult; Aged; Aged, 80 and over; Alzheimer Disease; Atrophy; Brain; Carbon Radioisotopes; Case-Contro

2001
In-vivo measurement of activated microglia in dementia.
    Lancet (London, England), 2001, Aug-11, Volume: 358, Issue:9280

    Topics: Adult; Aged; Aged, 80 and over; Alzheimer Disease; Atrophy; Brain; Carbon Radioisotopes; Case-Contro

2001
Platelet benzodiazepine binding in Alzheimer's disease.
    Biological psychiatry, 1990, Oct-01, Volume: 28, Issue:7

    Topics: Aged; Aged, 80 and over; Alzheimer Disease; Blood Platelets; Dementia, Multi-Infarct; Diagnosis, Dif

1990